Search results
Results From The WOW.Com Content Network
Phenytoin may accumulate in the cerebral cortex over long periods of time which can cause atrophy of the cerebellum. The degree of atrophy is related to the duration of phenytoin treatment and is not related to dosage of the medication. [23] Phenytoin is known to be a causal factor in the development of peripheral neuropathy. [24]
Phenytoin/pentobarbital (trade name Beuthanasia-D Special) is an animal drug product used for euthanasia, which contains a mixture of phenytoin and pentobarbital. [1] It is administered as an intravenous injection to give animals a quick and humane death.
Fetal hydantoin syndrome, also called fetal dilantin syndrome, is a group of defects caused to the developing fetus by exposure to teratogenic effects of phenytoin. Dilantin is the brand name of the drug phenytoin sodium in the United States, commonly used in the treatment of epilepsy .
The Journal of Cancer Research and Therapeutics is a peer-reviewed open access medical journal published by Medknow Publications on behalf of the Association of Radiation Oncologists of India. The journal covers research in oncology , radiation oncology , medical imaging , radiation protection , non-ionising radiation , and radiobiology .
Therefore, it is directly related to cellular quiescence, proliferation, cancer, and longevity. PI3K activation phosphorylates and activates AKT , localizing it in the plasma membrane . [ 1 ] AKT can have a number of downstream effects such as activating CREB , [ 2 ] inhibiting p27 , [ 3 ] localizing FOXO in the cytoplasm, [ 3 ] activating ...
Purple glove syndrome is caused by the intravenous anticonvulsant phenytoin. [3] This medication has many already established neurological side effects. However, glove syndrome is a rare, with prevalence ranging from 1.7% to 5.9%, but has very serious adverse effect that may lead to limb amputations.
Busulfan was approved by the US Food and Drug Administration (FDA) for treatment of chronic myeloid leukemia (CML) in 1999. Busulfan was the mainstay of the chemotherapeutic treatment of chronic myeloid leukemia (CML) until it was displaced by the new gold standard, imatinib, though it is still in use to a degree as a result of the drug's relative low cost.
Fosphenytoin, also known as fosphenytoin sodium, and sold under the brand name Cerebyx among others, is a water-soluble phenytoin prodrug that is administered intravenously to deliver phenytoin, potentially more safely than intravenous phenytoin. It is used in the acute treatment of convulsive status epilepticus. Fosphenytoin was developed in 1996.